Spero Therapeutics Inc (SPRO) Quote

SPRO under $2

SPRO under $2

SPRO under $2

SPRO under $2

SPRO...................................https://stockcharts.com/h-sc/ui?s=SPRO&p=W&b=5&g=0&id=p86431144783

SPRO 10Q due March 13

SPRO under $2

SPRO new 52 week low

SPRO new 52 week low

SPRO new 52 week low

SPRO under $2

News?

$SPRO YuuuuGE FDA News

Spero Therapeutics shares were up 14% at $1.62 after the company received written agreement from the U.S. Food and
Drug Administration, under a Special Protocol Assessment, on the design and size of its pivotal Phase 3 clinical trial
of tebipenem HBr in patients with complicated urinary tract infection, including acute pyelonephritis.

Urinary tract infection drug,$66m reviewed up to 525m coming,royalties on sales is astronomical

Pfizer paid $5m of $40 and $80m total coming for license agreement,many more deals coming ,some phase 3 trials near done OMG THE BIG DEALS COMING

Look at the candle on this chart 6 month record high,now look back to see what happens with big vol

Look at the candle on this chart 6 month record high,now look back to see what happens with big vol

Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming

Relative vol up 28Xs ,buy vol up 1000s% I AM FOLLOWING THE $ ppl with big $ know something huge coming

ive had some strange experiences with stocks but this one has me baffled but not beaten..

someone just unloaded a boat load and or shorted same. halfway around the cape and battered by high winds but not going anywhere. i cant

they will short this back down to .80 at this rate . eff me

folks keep walking away.. day after day after day.. ill be here im lashed to the mast of this bark as we get blistered around the cape

damn heavy unloading

big volume crashing again.. and i thought i was smart.. hahahahahastill bullish

must be some kind of inside news. this keeps falling and i dont get it.. but too late now .. this is the hill i die on or

a little retail short covering for the green. ill take it

another day of heavy downside volume in the cards..not good

shorts in control

GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.

GSK believed in SPRO enough to pay over 60 million at once, when investors get the same belief level it would in theory skyrocket, risk/reward and forward expectations are supposed to partially drive share price along with cash available to reduce risk of dilution, cash which GSK provided.

a little run into earnings. ill hold through it and beyond

https://finance.yahoo.com/news/spero-therapeutics-announces-closing-exclusive-130500913.html

maybe we get some interest from this
https://finance.yahoo.com/news/spero-therapeutics-inc-spro-expected-140102871.html

ill be here when the mkt cap is over a billion

https://finance.yahoo.com/news/spero-therapeutics-present-data-idweek-120500461.html

almost no pre opening trading...the waters have stilled.. it wont stay calm for long ..lets see which way it breaks

bought more i wont be bought off with impatience

enter the flipper

just when you have given up hope a volume burst and a price pop

Macd on one month about to cross lower unless they have premarket news, many will sell premarket without news so if they have something releasing it premarket would be best for loyal shareholders who would miss out on a new release later in the session.

ugly ugly day again....but in a sane world this is 10x the mkt cap it is today

grinding our way to fair value.. whatever that is well north of here

hopefully we hold these gains

“8:05a ET 10/3/2022 - Globe Newswire
Spero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program

GlobeNewswireOctober 03, 2022
Event is taking place on Thursday, October 6th at 11:30 a.m. ET


Event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH (Division of Infectious Disease, OHSU Medical School)

CAMBRIDGE, Mass., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a virtual R&D event on Thursday, October 6, 2022, at 11:30 a.m. Eastern Time.

The virtual event will feature a presentation by key opinion leader, Kevin L. Winthrop, MD, MPH, from the Division of Infectious Disease, OHSU Medical School. During his presentation, Dr. Winthrop will discuss the etiology, unmet medical need, and treatment landscape of non-tuberculous mycobacteria (NTM) pulmonary disease. Members of the Spero management team will provide an overview of the development program for SPR720, a potential novel first line oral therapy for NTM infections.

A live Q&A session will follow the formal presentations. To register for the event, please click here.

Dr. Winthrop Biography:

Kevin L. Winthrop, MD, MPH, Professor of Public Health, Infectious Diseases, and Ophthalmology at Oregon Health and Science University, is a former staff infectious disease epidemiologist from the U.S. Centers for Disease Control and Prevention's Division of Tuberculosis Elimination. He has co-authored over 300 publications, many detailing the epidemiologic and clinical aspects of nontuberculous mycobacterial diseases, tuberculosis, and other infections associated with rheumatic diseases and biologic immunosuppressive therapies. Clinically, he provides regional consultations for mycobacterial diseases and other chronic chest infections and serves as the medical consultant to the Oregon Public Health Division's TB control program. His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials. He has served as a primary or senior investigator in many of these clinical and epidemiologic studies, and frequently collaborates with the Pulmonary Department on studies related to bronchiectasis. He founded the NTM Research Consortium and associated Clinical Trials Network which facilitate collaborative, multi-site grants and clinical trials among patients with NTM. He is a member of the graduate faculty at OHSU where he mentors public health students, medical students, and physicians in post-graduate training.”

look out above...lets go friday

“If Spero’s license with Meiji is terminated, or if Meiji forfeits or loses its rights to develop, manufacture and commercialize tebipenem HBr and products that contain tebipenem HBr in any countries in the Meiji Territory, then GSK will have an exclusive first right to negotiate with Spero to add any such countries to the GSK Territory.
Under the terms of the License Agreement, Spero will receive an upfront payment of $66 million for GSK to secure rights to the medicine. Remaining potential payments are milestone based, and are as follows:

Event Milestone payments (up to)
Delivery of phase III programme
$150m
Total commercial milestone payments based on first sale (US/EU)
$150m
Sales milestone events

Net sales greater than $200m
$25m
Net sales greater than $300m
$25m
Net sales greater than $400m
$25m
Net sales greater than $500m
$50m
Net sales greater than $750m
$50m
Net sales greater than $1,000m
$50m
Total sales milestone payments:
$225m
Royalties
Low-single digit to low-double digit (if
sales exceed $1bn) tiered royalties
on net product sales.
Royalties are subject to reduction in the event of third-party licenses, entry of a generic product or expiration of patent and regulatory exclusivity prior to the tenth (10th) anniversary of the first commercial sale of a GSK Licensed Product in a particular country.
Spero will be responsible for the execution and costs of the follow-up Phase III clinical trial of tebipenem HBr. GSK will be responsible for the execution and costs of additional further development, including Phase III regulatory filing and commercialization activities for tebipenem HBr in the balance of the GSK Territory outside of the United States. Spero will also be responsible for providing and paying for the clinical supply of tebipenem HBr while GSK will be responsible for the costs of the commercial supply of tebipenem HBr. A joint development committee will be established between GSK and Spero to coordinate and review development activities for tebipenem HBr in the United States.”

a few smart shorts see the writing on the wall..and nd it just takes time to consolidate through the profits through the shorting through the day flippers and the criminals..takes time

red to green when you least expect it

start loading for $5 imo